Voxmind | $735,203 | (Jun 2, 2026)
Invertix | $1,977,831 | (Jun 2, 2026)
XCENA | $135,000,000 | (Jun 2, 2026)
Waiv, formerly Owkin Dx
France
- Paris
- 13/03/2026
- Unknown
- $33,000,000
Waiv has evolved to meet this moment:
Hundreds of novel innovations are entering clinical development each year, while biomarker testing complexity and costs are surging. As healthcare undergoes a broader shift toward precision care, treatment decisions, monitoring strategies, and patient pathways increasingly rely on high-dimensional data and advanced diagnostics.
Clinical diagnostics must keep pace with the scale and complexity of precision medicine, ensuring no patient is left behind.
Waiv, a spin-out of Owkin (https://www.owkin.com/), capitalizes on its industry-leading tech & AI stack, and clinically validated, already-deployed AI tests, such as RlapsRisk BC (https://www.owkin.com/diagnostics/rlapsrisk-bc), to unlock morphological insights and future-proof the clinical diagnostic workflow.
- Industry Biotechnology Research
- Website https://wearewaiv.com/
- LinkedIn https://www.linkedin.com/company/we-are-waiv/
Inherent | $50,000,000 | (Jun 2, 2026)
Gray Swan | $40,000,000 | (Jun 2, 2026)
Handshake(UK) | $3,200,000 | (Jun 2, 2026)
Sekai(US) | $26,000,000 | (Jun 2, 2026)
Human Archive (YC W26) | $8,200,000 | (Jun 2, 2026)
Perceptic | $12,000,000 | (Jun 2, 2026)
SpeedLabs | $6,500,000 | (Jun 2, 2026)
MokN | $15,000,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)